Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 14, 2023 2:42pm
167 Views
Post# 35735064

RE:RE:“Highly likely to succeed”

RE:RE:“Highly likely to succeed”I agree.

But this may have to be an FDA decision/request.

And...another consideration.  The ARR (absolute risk reduction)  is likely to increase (on average) with each new patient.  This is becasue they have a better targeted patient popultion in Tigris, based on everything they have learned in Phase 3.  The final stats are an amalgum of Euprates 179 and Tigris 150.

The higher the ARR perhaps the higher the price that the treatment might command once commecialization begins.

e.g.  Spectral assumed $ 6750 per column in their latest EBITDA analysis
Paradigm assumes $ 7750 per column in their discounted cashflow model

Maybe at 25-30% the price could be $8750? or more?

as an example $ 8750 is 30% higher revenues than $ 6750

Now add in extra columns for some patients (studies have shown improved outcomes for > 2 columns for some patients.).  Will EDEN shed light on this?
<< Previous
Bullboard Posts
Next >>